Admedus Ltd

Receive alerts
Market Cap:
$53.18 m
0.09 AUD
52 weeks high
52 weeks low

Admedus is a structural heart company that develops, commercialises and distributes next generation medical technologies and devices. Our mission is to provide patients around the world with a better quality of life through access to our leading medical solutions and products.

Our Technology

Admedus is committed to improving healthcare outcomes for patients worldwide through research, innovation and the development of next-generation medical technologies.

Admedus is excited by science. We love innovation. And never shy away from a challenge.

Our proprietary ADAPT® technology was invented by Admedus VP Cardiovascular Science, Professor Leon Neethling, a renowned pioneer of research and development in his field.

Primarily used in restorative structural heart repair and reconstruction, ADAPT® biomaterial scaffolds offer superior resistance to calcification with more than nine years of clinical evidence showing no degradation or calcification.

The potential of this technology is almost beyond measure, as we constantly look to evolve its purpose and application.

All Admedus ADAPT® products are manufactured in, and distributed from, our state-of-the-art biomanufacturing facility which has substantial capacity to expand and includes an in-house research and development laboratory.

Like our ADAPT® products, we’re always looking for new opportunities to grow, expand and transform our business with a range of exciting development projects always underway.

(click here for more information)


Through investment in world-class research and partnerships, Admedus is uniquely positioned to develop, commercialise and distribute a range of clinically-superior healthcare solutions.

Admedus is committed to developing, and distributing, products that are backed by solid clinical evidence and offer an improved experience for patients and physicians.
In addition to our research and development, bio-manufacturing  and portfolio of tissue products, we also offer a range of infusion solutions and medical products that support enhanced treatment, promote healing and can make a positive difference to the lives of patients.

(click here for more information)


Last updated 25th July 2019

Wayne Paterson
President and CEO

Wayne has held numerous, senior positions in multi-national companies and has lived in seven countries during the past 25 years. Through his career, he has been responsible for building and managing multibillion dollar businesses throughout the world, including mergers, integrations, acquisitions and major restructures as President and CEO.

From 2005 to 2013 he held senior positions at Merck KGaA, most recently as President of Europe, Canada and Australia. Prior to this, he was President of Emerging Markets, President of Japan and Global Head of Cardiovascular medicine.

Between 1999 and 2005, Wayne served at Roche Pharmaceuticals where he was Head of Pharmaceuticals in Roche’s South Korean operation, following his role as Head of Commercial Operations for Roche China based in Shanghai.

From April 2015 until November 2016, Wayne served as a Non-Executive Director of Cepheid (NASDAQ: CHPD), a molecular diagnostics company based in California.
He holds an MBA from the University of Southern Queensland, and a degree in business studies from the Queensland University of Technology.

He has also studied business courses at North Western University (Kellog School of Management) in Chicago, IMD Business School in Switzerland, INSEAD in France and Hong Kong University of Technology.

John Seaberg

Between 2007 and 2014, John was Founder, Chairman and CEO of NeoChord Inc, a venture capital-backed company commercialising technology developed at the Mayo Clinic for the repair of the mitral valve via minimally invasive techniques.

Previously, John served at Guidant Corp from 1996 until 2006. During ten years at Guidant, he served in various executive level positions in sales and marketing, including Director of Bradycardia Marketing for Cardiac Rhythm Management (CRM) and Vice President of Sales for Cardiac Surgery, in which he managed a field sales team of more than 600 people and over $1 billion in revenue.

In 1991, John co-founded ACIST Medical and served as its first President and CEO. He was also the founder and CEO of Seaberg Medical, a regional distributor of implantable cardiovascular devices. He lives in Minneapolis and holds a Bachelor of Arts in Speech Communications from the University of Minnesota and a Masters in Business Administration (MBA) from the Carlson School of Management, also at the University of Minnesota.

Stephen Denaro
Non-Executive Director and Company Secretary

Stephen has extensive experience in mergers and acquisitions, business valuations, accountancy services, and income tax compliance gained from positions as Company Secretary and Chief Financial Officer of various public companies and with major chartered accountancy firms in Australia and the United Kingdom. He provides company secretarial services for a number of start-up technology, ASX listed (Anatara Lifesciences Limited “ASX: ANR” and Oventus Medical Limited “ASX: OVN”) and unlisted public companies. He is also a Non-Executive Director and Chair of the Audit & Risk Committee of a not for profit company, National Affordable Housing Consortium Limited.

Stephen has a Bachelor of Business in Accountancy, Graduate Diploma in Applied Corporate Governance and is a member of the Institute of Chartered Accountants in Australia & New Zealand, and the Australian Institute of Company Directors.

Wenyi Gu
Non Executive Director

Dr Gu currently works as a Research Fellow for the Australian Institute for Bioengineering and Nanotechnology at the University of Queensland (UQ) where he began his post-doctoral work in 2001.

Dr Gu holds a master’s degree in veterinary science and completed his PhD study in biochemistry and molecular biology at Australian National University (ANU) and later worked at John Curtin Medical School (ANU). He also held a Peter Doherty Fellowship (2006-2009) and was supported by the National Health and Medical Research Council (NHMRC) to work at Harvard Medical School, Harvard University as a visiting fellow.

Before engaging in nanomedicine (focusing on drug delivery and cancer therapy), he worked on RNAi-based gene therapy for several years at Translational Research Institute (TRI).

Dr Gu’s research has been extensively published in respected industry journals such as Nature Communications, Ad. Materials, ACS Nano and PNAS USA. He is a Nominee Non-Executive Director for major shareholder, Star Bright Holding Ltd.

Dr Yanheng Wu
Non-Executive Director

Dr Wu currently serves as President and Managing Director of Constellation International Group Holdings Ltd. Dr Wu also established the Guangzhou Hearty-Care Biotechnology Ltd, a medical technology company.

Dr Wu completed his PhD in tumour immunotherapy and nanocarrier technology at The University of Queensland. He holds multiple biomedical patents and is well published domestically and internationally.

Before commencing his PhD, he worked at Sun Yat-sen University Cancer Center as a researcher. He also holds a Bachelor of Clinical Medicine from Guangzhou Medical University.


Last updated 25th July 2019


Registered Office

860 Blue Gentian Road
Suite 340
Eagan MN 55121
United States

T +1 651 493 0606

Customer Service:

T +1 855 300 1062
F +1 877 398 1055


Registered Office

Bahnhofstrasse 98/100
8001 Zurich

Customer Service:


T 0800 022 5294
F 0800 022 2473


T 800 878 124
F 800 794 392


T 0800 919 710
F 0800 917 173


T 0800 180 0173
F 0800 180 0181

United Kingdom

T 0800 151 0189
F 0800 151 0190


Registered Office

Toowong Tower
Level 3, 9 Sherwood Rd
Toowong QLD 4066

PO Box 1159
Milton 4064

T +61 (0)7 3152 3200
F +61 (0)7 3152 3299

Australian Customer Service:

T 1300 550 310
F 1300 880 398



Last updated 25th July 2019

Admedus Limited

ABN 35 088 221 078


John Seaberg - Chairman
Wayne Paterson - Chief Executive Officer
Stephen Denaro - Non-Executive Director & Company Secretary
Wenyi Gu - Non-Executive Director
Dr Yanheng Wu - Non-Executive Director

Registered Office

Toowong Tower
Level 3, 9 Sherwood Rd
Toowong QLD 4066

Telephone: +61 7 3152 3200
Facsimile: +61 7 3152 3299
Email: [email protected]

Share Registry

Computershare Investor Services Pty Ltd
Level 2, Reserve Bank Building
45 St Georges Terrace
Perth, Western Australia 6000

Telephone: 1300 557 010 (within Aust)
+61 3 9415 4000 (outside Aust)
Facsimile: +61 3 9473 2500

Patent Attorney

Winthrop and Weinstine
225 S 6th St Ste 3500
Minneapolis MN 55402 · +1 (612) 604-6400

Solicitors - Jones Day

Riverside Centre
Level 31/123 Eagle St
Brisbane City QLD 4000


HLB Mann Judd
Level 4, 130 Stirling Street
Perth Western Australia, 6000



Last updated 25th July 2019